Bliss GVS Pharma Q4 FY26 Results: Board Approves FY26 Results Recommends 100 Percent Dividend AGM July 15 2026

Bliss GVS Pharma Q4 FY26 results were approved by the board on 12 May 2026, with the company recommending a 100 percent final dividend (Re 1 per equity share of face value Re 1 each) for FY26, subject to shareholder approval at the 41st Annual General Meeting scheduled for July 15, 2026. The Bliss GVS Pharma Q4 FY26 board meeting also confirmed the company’s audited standalone and consolidated financial results for the quarter and full year ended March 31, 2026. Bliss GVS Pharma is one of India’s largest manufacturers of suppositories and pessaries, with a significant global export footprint in Africa, Latin America, and Southeast Asia. For the trailing twelve months, the company reported revenue of approximately Rs 868 crore and profit of approximately Rs 114 crore.

Click Here – Get Free Investment Predictions

Bliss GVS Pharma Q4 FY26 Key Financial Highlights

Parameter	FY26 (TTM)	Reference
Revenue (Trailing 12 Months)	Approx. Rs 868 crore	FY25 reference
Net Profit (TTM)	Approx. Rs 114 crore	FY25 reference
Q3 FY26 PAT	Rs 24.78 crore	Sequential base
Dividend	100% (Re 1 per share)	41st AGM: July 15, 2026
Market Cap	Approx. Rs 2,883 crore	As of May 12, 2026
NSE Ticker	BLISSGVS	Sector: Specialty Pharmaceuticals

Screen the best stocks on the Univest Screener.

Investors tracking SKF India Industrial Q4 FY26 results can monitor the latest price, analyst ratings, and earnings updates on the Univest Screener for real-time data.

Bliss GVS Pharma Q4 FY26 Business Overview and Performance

Bliss GVS Pharma Q4 FY26 board meeting on May 12, 2026, approved the audited financial results and recommended a 100 percent final dividend, reflecting the company’s stable cash flow generation and shareholder return focus. Bliss GVS Pharma is internationally known as one of the largest manufacturers of suppositories and pessaries, serving healthcare markets across Africa, Latin America, Southeast Asia, and other emerging markets. The company’s business model is built on regulated market exports with long-term supply relationships with global pharmaceutical companies and healthcare agencies.

The company has demonstrated resilience through its export-focused pharmaceutical manufacturing model. Q3 FY26 PAT was Rs 24.78 crore on revenue of Rs 218.25 crore. The company has also recently established a wholly-owned subsidiary in the Democratic Republic of Congo (DRC), expanding its footprint in Africa. Bliss GVS Pharma has gained ICRA’s A- (Stable) credit rating for its facilities, reinforcing its financial credibility. The Bliss GVS Pharma Q4 FY26 results mark the completion of a year in which the company maintained its export-led growth trajectory in specialty pharmaceutical dosage forms.

The board of Bliss GVS Pharma recommended a 100 percent final dividend (Re 1 per equity share) for FY26, subject to shareholder approval at the 41st Annual General Meeting on July 15, 2026.

Investors tracking SKF India Industrial Q4 FY26 results can monitor the latest price, analyst ratings, and earnings updates on the Univest Screener for real-time data.

Bliss GVS Pharma FY27 Outlook

Post Bliss GVS Pharma Q4 FY26 results, the FY27 outlook will be shaped by new market expansion in the DRC and other African markets, renewal and growth of existing long-term supply contracts, and the company’s ability to scale up new dosage form capabilities. The specialised nature of Bliss GVS Pharma’s products (suppositories, pessaries, and other alternative dosage forms) provides a competitive moat with limited domestic competition, supporting sustained export-led revenue growth.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on Bliss GVS Pharma Q4 FY26 Results

What dividend did Bliss GVS Pharma recommend for FY26?

Ans. Bliss GVS Pharma recommended a 100 percent final dividend (Re 1 per equity share of face value Re 1 each) for FY26, subject to approval at the 41st Annual General Meeting scheduled for July 15, 2026.

When did Bliss GVS Pharma announce Q4 FY26 results?

Ans. Bliss GVS Pharma’s board approved audited Q4 FY26 and FY26 financial results on 12 May 2026, with findings filed with BSE and NSE.

What is Bliss GVS Pharma’s business?

Ans. Bliss GVS Pharma is one of India’s largest manufacturers of suppositories and pessaries, a specialist pharma company serving global healthcare markets across Africa, Latin America, and Southeast Asia with specialty dosage form medicines.

Where can I track Bliss GVS Pharma Q4 FY26 live data?

Ans. Track Bliss GVS Pharma live price, analyst ratings, and Q4 FY26 earnings updates on the Univest Screener for real-time data and research on the specialty pharmaceuticals sector.

The SKF India Industrial Q4 FY26 results performance reflects the company’s position in its sector.

The SKF India Industrial Q4 FY26 results performance reflects the company’s position in its sector.

The SKF India Industrial Q4 FY26 results performance reflects the company’s position in its sector.

The SKF India Industrial Q4 FY26 results performance reflects the company’s position in its sector.

Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice. All financial data cited is sourced from BSE/NSE exchange filings and verified news sources. Investments in securities are subject to market risk. Consult a SEBI-registered investment advisor before making any investment decision.